<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03907215</url>
  </required_header>
  <id_info>
    <org_study_id>ID-078-114</org_study_id>
    <nct_id>NCT03907215</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects</brief_title>
  <official_title>A Single-center, Single-blind, Randomized, Placebo-controlled, Sequential Design Phase 1 Study With the Inclusion of Two Double-blind Nested Crossover Parts to Investigate the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to examine the drug-drug interactions between ACT-541468 and citalopram in
      healthy male and female subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-center, single-blind, randomized, placebo-controlled, sequential design Phase 1 study with the inclusion of two double-blind nested crossover parts</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind to the administration of ACT-541468 (participant). Single- and double-blind to the administration of ACT-541468 (Investigator, single-/double blind is dependent on treatment arm team). Single-blind study with the inclusion of two double-blind nested crossover parts, i.e., subjects will remain blinded to all administrations of ACT-541468.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline for Saccadic Peak Velocity (degrees/sec) to assess sedation</measure>
    <time_frame>From pre-dose to 8 hours after dosing on Day 1, Day 2, Day 3, Day 9, and Day 10</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-emergent AEs from study treatment administration up to EOS</measure>
    <time_frame>AEs from Day 1 to EOS; for up to 15 days post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-emergent SAEs from study treatment administration up to EOS</measure>
    <time_frame>SAEs from Day 1 to EOS; for up to 50 days post-dose</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A and B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>On Day 1 and Day 2, subjects will EITHER receive:
a single dose of 50 mg ACT-541468 (Treatment A) on Day 1 and a single dose of ACT- 541468 placebo (Treatment B) on Day 2 OR
a single dose of ACT-541468 placebo (Treatment B) on Day 1 and a single dose of 50 mg ACT-541468 (Treatment A) on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C, D, E, and F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>From Day 3 to Day 10, subjects will on each day receive:
• a single dose of 20 mg citalopram and EITHER a single dose of ACT-541468 placebo OR a single dose of 50 mg ACT-541468.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT541468</intervention_name>
    <description>50 mg; film-coated tablet for oral use</description>
    <arm_group_label>Treatment A and B</arm_group_label>
    <arm_group_label>Treatment C, D, E, and F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT541468 placebo</intervention_name>
    <description>film-coated tablet for oral use</description>
    <arm_group_label>Treatment A and B</arm_group_label>
    <arm_group_label>Treatment C, D, E, and F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>20 mg; tablet tor oral use; for single- or repeated dosing</description>
    <arm_group_label>Treatment C, D, E, and F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure.

          -  Healthy male and female subjects aged between 24 and 55 years (inclusive) at
             Screening.

          -  Body mass index of 18.5 to 29.9 kg/m2 (inclusive) at Screening.

          -  Women of childbearing potential must have a negative serum pregnancy test at Screening
             and a negative urine pregnancy test on Day -1. They must consistently and correctly
             use a highly effective method of contraception, be sexually inactive, or have a
             vasectomized partner.

          -  Women of non-childbearing potential (i.e., postmenopausal, with previous bilateral
             salpingectomy, bilateral salpingo oophorectomy or hysterectomy, or with premature
             ovarian failure, XY genotype, Turner syndrome, uterine agenesis).

          -  Healthy on the basis of physical examination, cardiovascular assessments, and clinical
             laboratory tests.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.

          -  Modified Swiss Narcolepsy Scale total score &lt; 0 at Screening or history of narcolepsy
             or cataplexy.

          -  Any contraindication to citalopram or any other selective serotonin reuptake
             inhibitor.

          -  History of cardiovascular disease (e.g., congenital long QT syndrome, arrhythmia).

          -  Relevant history of a suicide attempt or suicidal behavior.

          -  Personal or family history of psychiatric disorder(s).

          -  Individuals of Asian descent.

          -  History or clinical evidence of alcoholism or drug abuse within the 3-year period
             prior to Screening.

          -  Excessive caffeine consumption, defined as ≥ 800 mg per day at screening.

          -  Previous treatment with any prescribed medications (including vaccines) or
             over-the-counter (OTC) medications (including herbal medicines such as St John's Wort,
             homeopathic preparations, vitamins, and minerals) within 2 weeks or 5 terminal
             half-lives (t½; whichever is longer) prior to first study treatment administration.

          -  Ongoing, recurrent, or chronic hypokalemia or hypomagnesemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

